Teva recalls drugs in UK, Hong Kong

Teva recalled four batches of Desloratadine in the UK and three batches of Simvastatin in Hong Kong.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled two drugs in separate incidents in the UK and Hong Kong. Both recalls are partial, limited to specific batches. The financial effect on Teva is immaterial, but no drug company likes a recall.

Two weeks ago in the UK, Teva recalled four batches of 5 mg tablets of Desloratadine, for the treatment of allergic rhinitis, after Teva discovered during stability testing that the tablets had higher levels of impurities than they should. The company said there were no safety issues. Teva subsequently updated the recall after getting the original batch numbers wrong. Desloratidine is made by Germany's ratiopharm, which Teva acquired a few years ago.

In Hong Kong, the Department of Health ordered the recall of three batches of Simvastatin, a prescription generic drug for reducing cholesterol, because of a packaging mistake. A customer found that a packet of 10 mg tablets contained 20 mg tablets.

Teva said in response, "Two weeks ago in the UK, Teva recalled a limited number of batches of 5 mg tablets Desloratadine ratiopharm, following a routine stability test. A recall was also made of Simvastatin in Hong Kong, because of labeling error on the package. We emphasize that although there was no risk to patients taking the two drugs, the company preferred to proceed with extra caution and recalled the products."

Published by Globes [online], Israel business news - www.globes-online.com - on February 27, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס